

**Overview**
**Useful For**

Monitoring serum pregabalin (Lyrica) concentrations, assessing compliance, and adjusting dosage in patients.

**Method Name**

Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)

**NY State Available**

Yes

**Specimen**
**Specimen Type**

Serum

**Specimen Required**

**Collection Container/Tube:** Red top

**Submission Container/Tube:** Plastic vial

**Specimen Volume:** 1 mL

**Collection Instructions:**

1. Draw specimen immediately before next scheduled dose.
2. Spin down within 2 hours of draw and move serum to plastic vial.

**Forms**

If not ordering electronically, complete, print, and send a [Therapeutics Test Request](#) (T831) with the specimen.

**Specimen Minimum Volume**

0.5 mL

**Reject Due To**

Gross hemolysis	OK
Gross lipemia	OK
Gross icterus	OK

**Specimen Stability Information**

Specimen Type	Temperature	Time	Special Container
Serum	Refrigerated (preferred)	28 days	
	Ambient	28 days	
	Frozen	28 days	

---

## Clinical and Interpretive

### Clinical Information

Pregabalin (Lyrica) is an anticonvulsant drug used to treat partial seizures in patients and is a more potent successor to gabapentin. Pregabalin is commonly used for neuropathic pain and fibromyalgia. This test can be used by physicians to assess compliance and may be clinically useful in patients with renal failure who generally require lower dosages. Therapeutic and toxic ranges are not well defined. Therapeutic concentrations are reported to be from 2 to 5 mcg/mL, while toxicity may occur at concentrations above 10 mcg/mL.

### Reference Values

2.0-5.0 mcg/mL

### Interpretation

The serum concentration should be interpreted in the context of the patient's clinical response and may provide useful information in patients showing poor response, noncompliance, or adverse effects.

### Cautions

This test cannot be performed on whole blood.

Specimen must be spun and serum removed from collection tube within 2 hours of draw.

### Clinical Reference

1. Baselt R: Disposition of Toxic Drugs and Chemicals in Man. 10th edition. Biomedical Publications. Seal Beach, CA, 2014
2. Hiemke, C, Baumann P, Bergemann N, et al: AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry 2011;44:195-235

## Performance

### Method Description

Samples are extracted with analyte detection by mass spectrometry.(Unpublished Mayo method)

### PDF Report

No

### Day(s) and Time(s) Test Performed

Tuesday; 12:01 a.m.

### Analytic Time

Same day/1 day

### Maximum Laboratory Time

7 days

### Specimen Retention Time

14 days

---

**Performing Laboratory Location**

Rochester

**Fees and Codes****Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact [Customer Service](#).

**Test Classification**

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

**CPT Code Information**

80366

G0480

**LOINC® Information**

Test ID	Test Order Name	Order LOINC Value
PGN	Pregabalin, S	47414-8

Result ID	Test Result Name	Result LOINC Value
65119	Pregabalin, S	47414-8